FPL 65447, a selective D, receptor agonist with a potential for the acute treatment of renal and cardiac failure and of sepsis and septic shock, was administered to beagle dogs by continuous intravenous infusion for a maximum of 14 days. Ophthalmoscopical examination revealed dose-related changes in the eye and associated structures, consisting of foci of retinal discolouration, corneal changes including oedema, keratitis, opacities and neovascularisation, and inflammation of the iris, periorbital tissues, and adnexa. Microscopical examination confirmed the presence of inflammatory lesions in the eye. These were predominantly histiocytic and were mainly focal circumscribed lesions. More diffuse inflammation with a granulocytic and lymphocytic component was also encountered in the limbus and uveal tract. A predominantly interstitial histiocytic adenitis involving various glandular structures associated with the eye and adnexa was also identified. Possible mechanisms to account for the histiocytic changes are discussed.
INTRODUCTION
FPL 65447 (4-[2-aminoethyl1-3-[2-{ 3-hydroxyl-4-methylphenyl}ethyl]-1,2-benzenediol hydrochloride, molecular weight 328.8) is a selective D, receptor agonist with a weak neuronal uptake 1 blocking profile. Selectivity of the compound has been demonstrated by its relative lack of 8, or B2 adrenoceptor activity, although some a2 activity has been identified. The pharmacological activity resulting from this selective profile of receptor activity is demonstrated by dose-related renal vasodilatation resulting in enhanced renal blood Row with minimal effects on blood pressure or heart rate in the anaesthetised dog. The effect is rapid in onset and recovery and'there are 110 indications of undesired prejunctional D, effects. Compounds with such activity are likely to be useful in improving splanchnic blood flow without the limitations of adrenoceptor stimulation associated with the use of dopamine (10) . Such compounds could have a potential therapeutic role in the treatment of renal or cardiac failwe and of sepsis and septic shock.
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It is now well established that D, agonists produce arteriopathies in the rat following intravenous infusion. These lesions, consisting of medial necrosis, medial haemorrhage, and penarterial inflammation, were found predominantly in the vasculature of the mesenteric bed and have not been identified in other species (4) . There is no published evidence of this class of compound producing histopathological changes in the beagle dog.
We have demonstrated that FPL 65447 can induce rat-specific arteriopathies when administered by continuous intravenous infusion (Kerry and Wakefield, unpublished observations). FFL 65447associated pathology has also been identified in the t$agle dog, and in this paper we describe novel ophthalmological bhanges and corresponding light microscopic findings in a 14-day continuous intravenous infusion toxicity study. This study formed part of the initial preclinical safety evaluation package for this compound.
Manufacturing Ltd., Hull), to give working concentrations of 0.29,0.88, and 2.65 mg-ml-I, calculated as the base.
All solutions were prepared freshly each day. Any solution remaining at the end of a 24-hr infusion period was discarded and replaced with fresh solution. Analysis of the test solutions confirmed stability over this time period.
Animals. Twelve male beagle dogs (Bantin and
Kingman, Hull) were randomly assigned to groups of 3 animals each. An extra replacement animal was subsequently added to the group receiving the highest dose of compound. The animals were 4-7 mo old, clinically healthy, and housed in sawdust-free runs under standard laboratory conditions. Surgical Procedures. Each dog was premedicated with approximately 0.4 mg ofacetylpromazine (ACP, C-Vet Ltd., Bury St. Edmunds) intramuscularly and approximately 500 pg atropine sulphate (atropine sulphate for injection, Animal Care Ltd., Grimsby) subcutaneously. Anaesthesia was induced with thiopentone sodium (intraval sodium, RhBne-Poulenc Rorer Ltd., Eastbourne) titrated intravenously using a dose ofapproximately 20 mg-kg-I and maintained using 0.5% halothane (Fluothane, ICI, Macclesfield) with a 1:l mixture of oxygen and nitrous oxide, delivered via an endotracheal tube.
A 4-cm incision was made in the neck over the left jugular vein and the vein located and exposed. An intravenous cannula (Tygon surgical quality tubing, Norton) was inserted into the jugular vein and advanced to within approximately 2 cm of the heart. A radioopaque solution (Hypaque 859'0, Sterling Research Laboratories, Guildford) was introduced, and the position of the cannula was determined by radiography and adjusted as necessary. The cannula was secured in the vein with Ethibond (Ethicon Ltd., Edinburgh) ligatures, externalised through the skin in the dorsal neck region, and anchored by a skin button. The incisions were closed using Polyamid sutures (B. Braun Melsungen AG) following dusting with penicillin powder (Crystopen, Glaxo, Greenford). The intravenous cannula was connected to a section of sterile silastic tubing (Esco Rubber, Feltham) using all plastic connectors. This in turn wqs connected to the reservoir containing 5% dextrose (Viaflex bag, Baxter-Travenol Ltd., Thetford), the control vehicle, via a 3-way plastic tap. The infusion was controlled using a Cormed pump (Harvard Bioscience, South Natick, MA). The pump and reservoir were contained in specially designed jackets worn by each dog; these were connected, and infusion of 5% dextrose was started during the later stages of anaesthesia and during the recovery period. An analgesic (Temgesic Injection, Reckitt and Colman, Hull) at a dose of 0.5 mg.kg-' was adminis-tered subcutaneously to all animals on completion of surgery.
When recovered from the anaesthetic, the dogs were maintained on an infusion of 5% dextrose for a minimum of 7 days at a target rate of 1 ml-kg-'. h-'. Control animals were then infused with vehicle at a target rate of 1 rnl.kg-'-h-' for 14 days, while the other animals were infused with FPL 65447 at 5, 15, or 45 pgekg-lernin-' (7.2, 21.6, or 64.8 mg. kg-'.day-'), at the same rate and for the same duration. Dose selection was based on the intended clinical dose and multiples of this dose, derived from the pharmacological profile.
Clinical Observations. A full range of in-life clinical measurements and parameters were recorded. All animals were examined 3 times daily for signs of adverse reaction to treatment.
Ophthalinoscopic Examiiiation. The eyes of all animals were subject to a thorough examination, once prior to commencement of treatment and at term following 14 days of dosing or earlier, as indicated by clinical condition. Pupillary reflexes, both direct and consensual, and corneal reflexes were initially evaluated, following which 1 drop of a mydriatic [0.5% Mydriacyl, Alcon (UK) Laboratories Ltd., Watford] was instilled into each eye. Once mydriasis was established, funduscopic examination was performed using a Keeler indirect ophthalmoscope, and slit-lamp biomicroscopy was camed out using a hand-held Kowa SL5 slit lamp. All abnormalities were recorded.
Tissue Examination. The animals were sacrificed by intravenous injection of sodium pentobarbitone, and a complete necropsy was carried out. Tissues were fixed in 10% buffered formalin, with the exception ofthe eyes, which were fixed in Davidson's fluid, processed by standard histological techniques, embedded in paraffin wax, sectioned (4 pm), and stained with haematoxylin and eosin. Findings for eyes and intraorbital lacrimal glands only are reported in this communication.
RESULTS

Clinical Obsendtions Relating to the Eye
Two dogs, both of which received 45 pg-kg-'. min-' FPL 65447, had to be removed prematurely from the study as a result of unacceptable clinical signs. These included pyrexia, dyspnoea, and gross ocular lesions. The first animal was sacrificed on day 10 and the second on day 1 1 of dosing. No ocular effects were seen in animals receiving the lowest dose of FPL 65447 (5 pg-kg-'.min-'), whereas 1 animal from the intermediate dose group (1 5 pg-kg-' emin-') showed bilateral conjunctivitis at term. Bilateral conjunctivitis with mucoid discharge became apparent from day 8 onward in 1 animal and on days 9, 11, and 12, respectively, in the other 3 animals in the group receiving 45 pg.kg-'-min-' FPL 65447. In 2 of these cases, eyelids were swollen, resulting in partial blepharospasm. Some clodding of the cornea was apparent in the animal showing changes in the eye on day 1 I. Affected animals were treated with betamethasone eye drops (Betsolan, Pitman Moore Ltd., Uxbridge) as soon as signs of conjunctivitis were detected. This treatment improved but did not completely resolve the condition. ' 
Ophthalmoscopic Examination at Termination
Ophthalmoscopic examination confirmed the majority of clinical observations already described and revealed additional changes in the eye and associated structures. The distribution of these changes is summarised in Table I. In 2 animals receiving 45 pg-kg-l-min-l FPL 65447, incomplete dilatation of the pupil in response to a mydriatic, in 1 case with elliptical distortion, made funduscopic examination difficult. Examination of the tapetal fundus revealed numerous foci of grey/blue discolouration, giving the ret-. inas a mottled appearance in one of these animals and in a third animal from this group. The tapetal areas adjacent to these foci appeared normal, as did the non-tapetal region. No evidence of retinal detachment or other retinal changes were seen. These animals responded to simple visual stimuli, indicating no gross impairment of visual acuity. Three ofthe four animals receiving 45 pg-kg-'-min-l FPL 65447 displayed bilateral changes in the cornea. The affected dogs showed corneal oedema, and 1 had opacities in the superficial layers of the cornea. The corneas of a second animal appeared mottled with associated keratitis and opacities in the superficial layers while neovascularisation was evident in the third animal. Intis and vascular congestion of the sclera were detected in 1 animal. Inflammatory involvement of the periorbital tissue, conjunctiva, membrane nictatans, and eyelids was found in these 
Microscopic Observations
Microscopic examination revealed inflammatory lesions in the eye and adnexa. The incidence and distribution of these changes are shown in Table 11 .
Microscopic ocular changes were detected when given FPL 65447 at a rate of 15 and 45 pg-kg-'. min-l. At 15 pg.kg-'.min-l, only 1 ofthe 3 treated animals was affected, but at the highest dose of FPL 65447, 45 pg-kg-l.min-l, changes were seen in all animals. The changes were predominantly histiocytic in nature, with no or only limited lymphocytic or granulocytic involvement, and were mainly focal, circumscribed lesions. Figure 1 shows a focal lesion in the uveal tract adjacent to the ciliary body and trabeculae. A higher magnification of this lesion, illustrating the predominantly histiocytic component, is shown in Fig. 2 . These lesions had granulomatous characteristics, but there was no evidence of a foreign body presence. Further examples of the histiocytic lesions taken from the iris, ciliary body, and ciliary processes and exhibiting a granulomatous appearance are illustrated in Figs. 3-5 .
More diffuse changes with a granulocytic and lymphocytic component were also seen in the limbus and uveal tract of 1 animal (#11; Figs. 6 and 7) . A predominantly histiocytic adenitis involving the glandular structures of the eyelids, including the nictatans gland, and of the orbit, including the intraorbital lacrimal gland, was also present in 3 animals receiving 45 pg-kg-l-min-l FPL 65447. The adenitis was predominantly interstitial with only minimal involvement of the epithelium.
Necrosis associated with the inflammatory changes was also seen in the more severely affected animals (#11 and #12) receiving 45 pg.kg-l-min-l FPL 65447. This was particularly noticeable in the interstitium of the nictatans gland. Focal aggregations of acute and chronic inflammatory cells were also detected in 1 animal (#11) receiving 45 pg-kg-l. rnin-' FPL 65447. These were associated with the endothelium of the cornea (Fig. 8) and were also present in the aqueous humour.
There was no evidence of retinal degeneration in any of the dogs receiving FPL 65447. However, inflammatory cell infiltration into the tapetum was detected in 1 animal (#11) receiving 45 pg-kg-l. min-l FPL 65447.
DISCUSSION
The continuous intravenous infusion of FPL 65447, a novel D, agonist, in a 14 day study resulted in widespread and predominantly histiocytic inflammatory changes in the beagle dog. This paper concentrates on the manifestation of these changes in the eye, comparing the results of the clinical, ophthalmoscopic, and microscopic examinations. The compound-related histopathology of tissues and organs other than the eye and intraorbital lacrimal gland are the subject of a separate communication.
The correlation between the ophthalmological findings and the histological findings described in this study is poor. However, this lack of a good correlation is not unusual in investigations of this type and has been the subject of discussion elsewhere (3).
Changes in the tapetal cell layer of the beagle dog have been described following the administration of a wide variety of chemical classes. Tanaka et a1 (1 1) demonstrated tapetal colour changes and lymphocytic infiltration of the lacrimal glands following the administration of two 13-adrenergic blocking agents, carteolol and practolol. Schiavo et a1 (9) also observed lesions consisting of focal or multifocal areas of discolouration and pigmentation of the tapetal portion of the ocular fundus after oral administration of SCH 19927, a vasodilator with &adrenergic blocking activity. Light and electron microscopy showed tapetal cell degeneration and necrosis with macrophage, lymphocytes, and occasional plasma cells in the tapetum and adjacent choroid. The pathogenesis of these lesions is not known, although the vasodilating component at a sub-tapetal locus has been implicated. While discoloured focal or multifocal tapetal changes were observed during ophthalmological examination of the eyes of dogs given FPL 65447, no histological evidence of associated retinal degeneration was seen, although inflammatory cell infiltration of the tapetum was found in 1 animal given 45 pg-kg-l-min-' FPL 65447.
The results from this 1 study provide no information on the reversibility of these histiocytic changes on cessation of treatment, although the chronic granulomatous nature of the lesions would suggest that they have the potential to persist for considerable periods of time.
It is not know what role the blood-aqueous barrier plays, if any, in the aetiology of the eye lesions related to treatment with FPL 65447. However, the presence of inflammatory cells associated with the endothelium ofthe cornea and in the anterior chamber of 1 animal could suggest a perturbation of the blood-aqueous barrier. Inflammatory cells can infiltrate between the lamellae of the avascular substantia propria from blood vessels of the corneal limbus (2), but the absence of cellular infiltration at this site in this study indicates that the inflammatory cells in the anterior chamber may have amved via a different route, possibly from the uveal tract.
Little information exists on histiocytosis in the dog and the majority of published work is confined (6, 8) . These familial disorders do share certain features in common with the FPL 65447-induced eye changes described in this paper, although the general distribution of lesions in other organs differs. In his study on systemic histiocytosis in this breed, Moore (6) described conjunctival hyperaemia, chemosis, corneal oedema, anterior uveitis, and glaucoma in 3 of 6 animals. Histiocytic lesions were present in the sclera, conjunctiva, extraocular muscles, and retroorbital fat of 1 of these affected dogs, but unfortunately eye tissues were not available from the other 2 dogs exhibiting gross changes. The mechanism of formation of these histiocytic changes has not yet been established. FPL 65447 or its metabolites may exert a direct, adverse reaction on cells of the reticuloendothelial system, leading to an exaggerated and inappropriate histiocytic response to a relatively innocuous inflammatory stimulus. Histiocytic aggregation, particularly in the heart and liver of beagle dogs given a novel thromboxane antagonist by the oral route, has recently been described, and granuloma induction studies and in vitro migration studies suggest that monocyte/macrophage migratory activity is increased (1). It is not yet known how closely FPL 65447 lesions resemble thromboxane antagonist lesions, in terms of their morphological appearance, distribution, or mechanism of induction.
A second possibility is that FPL 65447 causes an as yet unidentified primary lesion (with a widespread, multifocal distribution) that results in an entirely appropriate secondary histiocytic response. There is increasing evidence in humans that release of uveal and retinal antigens from a traumatised eye stimulates a T cell-mediated auto-immune response and, in some cases, a sympathetic delayed hypersensitivity reaction can occur in the contralateral eye. These events manifest as a granulomatous reaction often involving the uveal tract and usually with giant cell involvement, in conditions such as sympathetic ophthalmitis (5). Compound-related cytotoxicity leading to some form of auto-immurle response, not necessarily with sympathetic involvement, could explain the histiocytic reaction in the dog.
A third alternative mechanism would require normal macrophage migratory activity in response to an innocuous inflammatory stimulus but a compromised ability of macrophages to deal with the stimulus once they reach their target. Under such circumstances, the inflammatory stimulus would persist for a longer time, resulting in further recruitment of impotent macrophages. The feasibility of this idea would depend on FPL 65447 having a specific cytotoxic effect on macrophage phagocytosis and/or macrophage digestive mechanisms. Studies looking at immunoreactive cytoplasmic lysozyme activity could be of value to help explore this hypothesis.
Using frozen sections, Moore (7) showed that lysozyme is readily detectable in canine histiocytic disorders. This enzyme is consistently expressed in systemic and malignant histiocytosis and also granulomatous panniculitis but is a less reliable marker in cutaneous histiocytoma. The differential expression in these various conditions may indicate the potential usefulness of this technique in determining the functional state of the histiocyte population in compound-induced lesions. Further investigations are being undertaken to help explain the pathogenesis of these lesions.
